Scientific consulting firm Exponent (NASDAQ:EXPO) reported in Q4 CY2025, with sales up 19.1% year on year to $147.4 million.
MENLO PARK, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today reported financial results for the second quarter of fiscal year 2025 ended July 4, 2025. “Second quarter ...
Exponent’s revenue has grown at a CAGR of 6% while EBITDA has at 8%. This has been driven by its fantastic business model and industry tailwinds. Exponent provides highly complex consulting services ...